JP2002512205A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002512205A5 JP2002512205A5 JP2000544365A JP2000544365A JP2002512205A5 JP 2002512205 A5 JP2002512205 A5 JP 2002512205A5 JP 2000544365 A JP2000544365 A JP 2000544365A JP 2000544365 A JP2000544365 A JP 2000544365A JP 2002512205 A5 JP2002512205 A5 JP 2002512205A5
- Authority
- JP
- Japan
- Prior art keywords
- ala
- solution
- ester
- ppix
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002749 aminolevulinic acid Drugs 0.000 description 39
- 239000000243 solution Substances 0.000 description 37
- -1 5-aminolevulinic acid ester Chemical class 0.000 description 25
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 23
- 229950003776 protoporphyrin Drugs 0.000 description 23
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 238000001126 phototherapy Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010668 complexation reaction Methods 0.000 description 5
- 150000003278 haem Chemical class 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229960000958 deferoxamine Drugs 0.000 description 3
- 229940099217 desferal Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 102100035831 Filensin Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 108010062616 filensin Proteins 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR98/05425 | 1998-04-22 | ||
| FR9805425A FR2777782B1 (fr) | 1998-04-22 | 1998-04-22 | Solution pour la preparation d'une substance pharmaceutique pour le diagnostic et/ou le traitement de lesions tissulaires |
| PCT/CH1999/000163 WO1999053962A1 (fr) | 1998-04-22 | 1999-04-22 | Solution pour le diagnostic ou le traitement de lesions tissulaires |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010051284A Division JP2010163445A (ja) | 1998-04-22 | 2010-03-09 | 組織病変部の診断または治療のための溶液 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002512205A JP2002512205A (ja) | 2002-04-23 |
| JP2002512205A5 true JP2002512205A5 (https=) | 2009-11-26 |
| JP4630395B2 JP4630395B2 (ja) | 2011-02-09 |
Family
ID=9525850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000544365A Expired - Lifetime JP4630395B2 (ja) | 1998-04-22 | 1999-04-22 | 組織病変部の診断または治療のための溶液 |
| JP2010051284A Pending JP2010163445A (ja) | 1998-04-22 | 2010-03-09 | 組織病変部の診断または治療のための溶液 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010051284A Pending JP2010163445A (ja) | 1998-04-22 | 2010-03-09 | 組織病変部の診断または治療のための溶液 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7348361B2 (https=) |
| EP (1) | EP1073472B1 (https=) |
| JP (2) | JP4630395B2 (https=) |
| AT (1) | ATE228018T1 (https=) |
| CA (1) | CA2327393C (https=) |
| DE (1) | DE69904033T2 (https=) |
| ES (1) | ES2188146T3 (https=) |
| FR (1) | FR2777782B1 (https=) |
| WO (1) | WO1999053962A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6992107B1 (en) | 1995-03-10 | 2006-01-31 | Photocure Asa | Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy |
| US6570001B1 (en) * | 1997-06-20 | 2003-05-27 | Institut Pasteur | Polynucleotides and their use for detecting resistance to streptogramin A or to streptogramin B and related compounds |
| DE10003620A1 (de) * | 2000-01-28 | 2001-08-02 | Asat Ag Applied Science & Tech | 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln |
| GB0018528D0 (en) | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| RU2218570C2 (ru) * | 2001-11-01 | 2003-12-10 | Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова | Способ флюоресцентной диагностики новообразований |
| EP1312353A1 (en) * | 2001-11-16 | 2003-05-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for hair removal |
| WO2007084981A2 (en) * | 2006-01-19 | 2007-07-26 | The Regents Of The University Of Michigan | System and method for photoacoustic imaging and monitoring of laser therapy |
| WO2008067438A2 (en) * | 2006-11-29 | 2008-06-05 | The Regents Of University Of Michigan | System and method for photoacoustic guided diffuse optical imaging |
| WO2009130893A1 (ja) | 2008-04-22 | 2009-10-29 | Ｓｂｉアラプロモ株式会社 | 膀胱がん検出方法 |
| TWI426133B (zh) * | 2008-05-30 | 2014-02-11 | Jfe Steel Corp | Production method of pig iron |
| EP2340821B1 (en) | 2008-10-27 | 2017-01-25 | SBI Pharmaceuticals Co., Ltd. | Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient |
| US20100256125A1 (en) * | 2009-04-06 | 2010-10-07 | Zila Pharmaceuticals, Inc. | Use of improved toluidine blue in photodynamic therapy |
| JP2011001307A (ja) * | 2009-06-19 | 2011-01-06 | Sbi Alapromo Co Ltd | ５−アミノレブリン酸による子宮頸がん判定・治療システム |
| CA2790827A1 (en) | 2010-03-01 | 2011-09-09 | Photocure Asa | Cosmetic compositions |
| KR101723834B1 (ko) | 2010-05-19 | 2017-04-06 | 에스비아이 파마 가부시키가이샤 | ５-아미노레불린산 또는 그 유도체를 유효성분으로 하는 항말라리아약 |
| EP2585111A1 (en) * | 2010-06-23 | 2013-05-01 | Photocure ASA | Hyperosmotic preparations comprising 5 -amino levulinic acid or derivative as photosensitizing agent |
| US9345904B2 (en) | 2011-07-01 | 2016-05-24 | Sbi Pharmaceuticals Co., Ltd. | Photodynamic therapy using photosensitizing agent or 5-aminolevulinic acid |
| JP6052736B2 (ja) | 2011-08-12 | 2016-12-27 | Ｓｂｉファーマ株式会社 | 敗血症の予防剤及び／又は治療剤 |
| US20140067024A1 (en) | 2012-08-30 | 2014-03-06 | Photocure Asa | Dual panel photodynamic therapy lamp |
| GB201221123D0 (en) | 2012-11-23 | 2013-01-09 | Photocure As | Device for photodynamic treatment |
| EP3567202B1 (en) * | 2014-06-11 | 2023-04-19 | Nippon Sheet Glass Company, Limited | Multiple-glazed glass unit |
| US9733187B2 (en) | 2015-03-06 | 2017-08-15 | King Saud University | Method of detecting bladder cancer by optical analysis of bodily fluids |
| GB201522398D0 (en) | 2015-12-18 | 2016-02-03 | Photocure As | Device for photodynamic therapy |
| JP2019527363A (ja) * | 2016-06-08 | 2019-09-26 | シーエフ ジーノーム， エルエルシー | 血液サンプルの細胞外小胞を安定化するための化学組成物及びその使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234940A (en) * | 1989-07-28 | 1993-08-10 | Queen's University | Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof |
| US5955490A (en) * | 1989-07-28 | 1999-09-21 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| ATE202076T1 (de) * | 1995-03-10 | 2001-06-15 | Photocure Asa | Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie |
| US5856566A (en) * | 1997-09-02 | 1999-01-05 | Dusa Pharmaceuticals, Inc. | Sterilized 5-aminolevulinic acid |
-
1998
- 1998-04-22 FR FR9805425A patent/FR2777782B1/fr not_active Expired - Fee Related
-
1999
- 1999-04-22 JP JP2000544365A patent/JP4630395B2/ja not_active Expired - Lifetime
- 1999-04-22 US US09/673,871 patent/US7348361B2/en not_active Expired - Lifetime
- 1999-04-22 WO PCT/CH1999/000163 patent/WO1999053962A1/fr not_active Ceased
- 1999-04-22 ES ES99913060T patent/ES2188146T3/es not_active Expired - Lifetime
- 1999-04-22 AT AT99913060T patent/ATE228018T1/de active
- 1999-04-22 DE DE69904033T patent/DE69904033T2/de not_active Expired - Lifetime
- 1999-04-22 EP EP99913060A patent/EP1073472B1/fr not_active Expired - Lifetime
- 1999-04-22 CA CA002327393A patent/CA2327393C/fr not_active Expired - Lifetime
-
2010
- 2010-03-09 JP JP2010051284A patent/JP2010163445A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4630395B2 (ja) | 組織病変部の診断または治療のための溶液 | |
| JP2002512205A5 (https=) | ||
| Svanberg et al. | Photodynamic therapy of non‐melanoma malignant tumours of the skin using topical δ‐amino levulinic acid sensitization and laser irradiation | |
| Van der Veen et al. | In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple irradiations | |
| JP2731032B2 (ja) | 光化学療法による悪性および非悪性病変の検出および治療方法 | |
| WO2002007630A1 (en) | Treatment for epithelial diseases | |
| WO1995007077A1 (en) | Photochemotherapeutic compositions containing 5-aminolevulinic acid | |
| EP1341464A1 (en) | Treatment for epithelial diseases | |
| JP2017503785A (ja) | 座瘡のパルス光力学的処置 | |
| Nkune et al. | Possible integration of artificial intelligence with photodynamic therapy and diagnosis: A review | |
| KR20140110757A (ko) | 질병을 치료하는 바이러스 불활성화 약물의 제조에서 광감각제의 용도 | |
| US20150141478A1 (en) | Series of drugs using photofrin to catalyze decomposition of hydrogen peroxide | |
| JP2002534483A (ja) | 代謝性骨障害または骨転移のための治療的組成物 | |
| EP1510225B1 (en) | Photochemotherapeutic use of 5-ALA in the treatment of acne | |
| De Blois et al. | In vivo pharmacokinetics of protoporphyrin IX accumulation following intracutaneous injection of 5-aminolevulinic acid | |
| Land | Porphyrin phototherapy of human cancer | |
| RU2146159C1 (ru) | Способ фотодинамической терапии злокачественных новообразований | |
| RU2119363C1 (ru) | Способ фотодинамической терапии опухоли | |
| JP2006523119A (ja) | 長期的な腫瘍停留を示す光増感剤を用いた多回投与プロトコールによる光線力学療法の改善された効果及び安全性 | |
| RU2169015C2 (ru) | Способ фотодинамической терапии злокачественных опухолей | |
| US20030083324A1 (en) | Photosensitizing ointment | |
| JP5265186B2 (ja) | 光照射による皮膚又は皮下軟部組織の血管性病変治療又は診断用薬剤 | |
| CN101219138A (zh) | 使用光动力疗法治疗巴瑞特氏食道症 | |
| Calin et al. | Photodynamic therapy of Walker tumors by multiple laser irradiation | |
| Kassuga et al. | Transepidermal application of medica-tion combined with photodynamic the-rapy in the treatment of actinic keratosis |